NCT07506057招募中2 期
An Open-label, Single-arm Phase II Clinical Study of Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
Xiujuan Qu1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年7月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- objective response rate (ORR)
研究概览
简要总结
his single-center phase II clinical study enrolls patients with unresectable locally advanced or metastatic HER2-overexpressing biliary tract cancer or urothelial carcinoma who have failed standard treatment. Participants receive trastuzumab in combination with serplulimab and chemotherapy. The study aims to evaluate the efficacy and safety of this regimen in this patient population. The primary endpoint is objective response rate (ORR). Secondary endpoints include overall survival (OS), progression-free survival (PFS), and safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 75 years, male or female.
- •Histologically or cytologically confirmed recurrent and/or metastatic advanced biliary tract cancer or urothelial carcinoma.
- •Disease progression after at least one prior line of systemic antitumor therapy. For patients who received systemic antitumor therapy during adjuvant therapy or concurrent chemoradiotherapy, progression occurring within 6 months after completion of therapy is considered as one prior line of therapy.
- •HER2 overexpression confirmed by immunohistochemistry (IHC) 3+ or IHC 2+ with in situ hybridization (ISH)+.
- •Left ventricular ejection fraction (LVEF) ≥ 50%.
- •No prior anti-HER2 therapy.
- •At least one measurable lesion according to RECIST version 1.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or
- •Adequate organ reserve function:
- •Urine protein ≤ 1+ on urinalysis or 24-hour urine protein < 1.0 g, and albumin > 2.7 g/dL.
- •Life expectancy ≥ 3 months as judged by the investigator.
- •Ability to provide written informed consent and understand and agree to comply with study requirements and assessment schedule.
- •Female patients of childbearing potential must agree to use highly effective contraception during the treatment period and for 12 weeks after the last dose; male patients must agree to use highly effective contraception during the treatment period and for 6 months after the last dose.
排除标准
- •Known HER2-negative or HER2-low expression.
- •Active autoimmune disease or history of autoimmune disease with potential for relapse. Patients with the following conditions are not excluded and may proceed to further screening
- •Presence of other malignancies within the past 2 years or currently, except for cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors (Ta, Tis, and T1).
- •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (at least once per month) within 14 days prior to enrollment.
- •Weight loss ≥ 20% within 2 months prior to enrollment.
- •Untreated chronic hepatitis B or chronic HBV carriers with HBV DNA > 500 IU/mL, or patients positive for HCV RNA. Patients with inactive HBsAg carriers, those with hepatitis B who have been treated and are stable (HBV DNA < 500 IU/mL), and those who have been cured of hepatitis C may be enrolled.
- •Known allergy to any study drug or excipient.
- •Palliative radiotherapy within 14 days prior to enrollment.
- •Prior anti-HER2 therapy.
- •Major surgery within 28 days prior to enrollment, except for minimally invasive procedures such as peripherally inserted central catheter (PICC) placement.
- •Major surgery within 28 days prior to enrollment, except for minimally invasive procedures such as peripherally inserted central catheter (PICC) placement.
- •Any underlying medical condition, or alcohol/drug abuse or dependence, that in the investigator's opinion would interfere with study drug administration or affect the interpretation of drug toxicity or adverse events.
- •Concurrent participation in another therapeutic clinical study.
结局指标
主要结局
objective response rate (ORR)
时间窗: From the first dose of study treatment until disease progression, intolerance, or start of new anti-cancer therapy, assessed every 6 weeks for the first 12 months and every 12 weeks thereafter, up to approximately 24 months.
Objective response rate (ORR) as assessed by the investigator according to RECIST version 1.1, defined as the proportion of patients achieving complete response (CR) or partial response (PR).
次要结局
- Overall Survival (OS)(From first dose until death, assessed every 6 weeks (Year 1) then every 12 weeks, and every 3 months during survival follow-up, up to approximately 24 months.)
- Progression-Free Survival (PFS)(From the first dose of study treatment until disease progression, intolerance, or start of new anti-cancer therapy, assessed every 6 weeks for the first 12 months and every 12 weeks thereafter, up to approximately 24 months)
研究者
Xiujuan Qu
Professor of Oncology
China Medical University, China
研究点 (1)
Loading locations...
相似试验
招募中
4 期
To evaluate how safe and tolerable Entrectinib is for Indian patients with advanced or metastatic solid tumors that have certain genetic changes.CTRI/2024/11/076926Roche Products (India) Pvt. Ltd20
尚未招募
2 期
Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)NCT07472478Guangdong Provincial People's Hospital32
尚未招募
2 期
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell LymphomasNCT07387848American University of Beirut Medical Center40
Enrolling By Invitation
2 期
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell CarcinomaNCT07312578Peking University48
尚未招募
2 期
A Clinical trial on vedigara silasathu parpam in the management of Azhal neerchurukku (Urinary tract infection) among patients attending OPD and IPD of Government Siddha Medical College and Hospital, PalayamkottaiCTRI/2024/05/068156Government Siddha Medical College and Hospital40